News

What's Going On With Cardiff Oncology Stock On Tuesday?

On Tuesday, Cardiff Oncology, Inc. (NASDAQ:CRDF) revealed initial data from the CRDF-004 Phase 2 trial, which evaluates onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The CRDF-004 phase 2 trial is currently enrolling patients with mCRC who have a documented KRAS or NRAS mutation. Onvansertib is added to SoC consisting of FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Patients are being randomized in a 1:1:

Sharp downgrades to US unit labor costs bode well for inflation outlook

WASHINGTON (Reuters) -U.S. unit labor costs grew far less than initially thought in the third quarter, pointing to a still favorable inflation outlook even though price increases have not moderated much in recent months. The report from the Labor Department on Tuesday also showed labor costs actually declined in the second quarter instead of rising as had been estimated last month. Moderate labor costs growth is likely to be welcomed by Federal Reserve officials when they hold their last meeting of year next week.

Johnson Outdoors Shares Slide After Q4 Earnings Miss, Hit By Market Challenges And Lower Margins

Johnson Outdoors Inc (NASDAQ:JOUT) shares plunged after the company reported its fourth-quarter 2024 results. The company’s sales grew 9.9% year-over-year to $105.9 million, missing the consensus of $114.99 million. Loss per share was $3.35, missing the consensus loss of $0.98. Gross margin contracted 600 bps to 23.5%, primarily due to higher promotional discounts, a shift in product mix favoring lower-margin items, and inventory reserves for slow-moving and obsolete stock. Gross profit was down

Ferguson Maintains FY25 Guidance Amid Tough Market, Q1 Misses Estimates

Ferguson Enterprises Inc. (NYSE:FERG) shares are trading lower after the company reported first-quarter results. The company reported net sales of $7.77 billion, which was 0.8% higher year over year, missing the consensus of $7.83 billion. Organic revenue fell by 0.3%, with a 1.1% negative impact from acquisition growth. Net sales in the U.S. business increased by 0.5%, while that in Canada grew by 6.3%. Gross margin contracted by 10 basis points to 30.1% in the first quarter. Adjusted operating